ASCO AI: ASCO Guidelines are now integrated into OpenEvidence The collaboration enables clinicians to access ASCO guideline-based recommendations, flowcharts, and supporting evidence directly through the AI platform. Learn more 👉 https://ow.ly/7AI750Zg1I7

🎗️ Global collaboration is critical to improving pediatric cancer outcomes St. Jude has been redesignated as a WHO Collaborating Centre for Childhood Cancer, reinforcing efforts to strengthen health systems, expand access to care, and improve outcomes. 🔗 https://ow.ly/jJcl50ZfmEs

🩸 #ASCOAI: Could a blood test predict #lungcancer ahead of diagnosis? 🫁 A machine learning–derived plasma protein signature can identify future lung cancer risk >5 years before diagnosis and was used in assessment of possible preventive treatment. 🔗 https://ow.ly/n4FQ50ZfmCj

✅ Expanding options in #BladderCancer: Phase II SURE-01 data suggest reduced-dose neoadjuvant sacituzumab govitecan has promising activity in muscle-invasive disease for patients unable or unwilling to receive chemotherapy. 🔹 Andrea Necchi, MD 🔗 https://ow.ly/9nTC50ZeKWY

⚠️ The FDA is warning of an ongoing shortage of stereotactic breast biopsy needles that could affect #breastcancer diagnostic care through early 2027. Providers are being encouraged to conserve supplies, diversify vendors, and communicate possible delays. https://ow.ly/Apyi50ZeKVP

☢️ New phase II data support the potential of Lu-177 dotatate in metastatic pancreatic neuroendocrine tumors. ➡️ longer PFS & better QoL vs sunitinib ➡️ late grade 2+ AEs could impact subsequent therapy 🔹 Eric Baudin, MD https://ow.ly/ixEG50Zep0G

🔟 -year FAST-Forward data support 1-week adjuvant radiotherapy as a standard option in breast cancer. The 26 Gy/5-fraction schedule showed disease control and safety for treatment to the breast or chest wall. 🔸 Adrian Murray Brunt, FRCR https://ow.ly/VTob50ZeoZA

🩸 AI may reduce biological noise in liquid biopsies The plasmaCHORD model uses cfDNA fragmentation patterns to identify if mutations originate from tumors or white blood cells ➡️ More accurate treatment decisions 🔸 Jenna Canzoniero, MD, MS https://ow.ly/n1rM50ZcSIE

💻 ASCO AI: AI in oncology operations Mia, Moffitt Cancer Center’s AI-powered information assistant, is helping reduce imaging delays, improve patient satisfaction, and free clinical teams to focus on higher-touch patient care. Learn more 👉 https://ow.ly/G9lJ50ZcSHx

🩸HPV-DeepSeek, a WGS assay, detected molecular recurrence in patients with HPV-associated #HeadAndNeckCancer up to 17.5 months before clinical recurrence and nearly twice as early as ddPCR. 🔹 Daniel Faden, MD Explore the findings ➡️ https://ow.ly/IIit50Zcn49

🩺 Geriatric assessments are an important tool for modern #cancercare. Stuart Lichtman, MD, FACP, FASCO, urges moving beyond ECOG, Karnofsky performance status to better identify vulnerabilities, predict toxicity, & personalize treatment for older adults with #cancer. 🔗 https://ow.ly/y90i50ZbWfY

🌎 Every patient. Every cancer. Everywhere. Eric J. Small, MD, FASCO, 2025-2026 ASCO President, shares his vision for translating scientific breakthroughs into meaningful outcomes across cultures, health systems, and resource settings worldwide. 🔗 https://ow.ly/YUPJ50ZbWcH

🧠 ASCO AI: CNSPredict, a machine learning clinicogenomic model, identified patients with metastatic breast cancer at high risk for brain metastases, including a subgroup with a 26% 2-year incidence rate. 🗣️ Presented by Luke R.G. Pike, MD, at ASCO 2026 🔗 https://ow.ly/bFfw50ZbNBh

🇭🇹 What does it take for a cancer prevention program to survive after its founder is gone? In this powerful reflection, Danta Bien-Aimé, BSN, RN, MMSc-GHD, explores the challenges of sustaining cervical cancer screening and treatment access in Haiti. 🔗 https://ow.ly/Ri0z50ZbNzR

🩺 The Society of Gynecologic Oncology has named Matthew A. Powell, MD, as its 2026 President. Dr. Powell's priorities include advancing education, member engagement, advocacy, and wellness across the gynecologic oncology community. https://ow.ly/zgPI50ZbNyt

🖥️ ASCOAI: Can AI support complex clinical reasoning? A study in Science found OpenAI {bot} o1 model outperformed physicians across several diagnostic and management reasoning tasks ➡️ Potential for AI as a clinical decision support tool. 🔗 https://ow.ly/tYC850ZabBi

🎶 New #survivorship data suggest music therapy may be a powerful tool for anxiety management. In the MELODY trial, music therapy matched CBT for reducing anxiety among cancer survivors, and improved fatigue, insomnia, mood, and quality of life. 🔗 https://ow.ly/XQXM50ZabzB

🔬The phase III NRG/RTOG 1005 trial found concurrent radiation boost during whole-breast irradiation was noninferior to sequential boost for ipsilateral breast recurrence in high-risk early #breastcancer. 🔸 Frank Vicini, MD, FACR, FASTRO, FABS https://ow.ly/kZTl50Z2Pb5

🆕 In the largest, multinational analysis of external beam RT in early-stage #HCC, survival outcomes were comparable to surgery, ablative therapies. ➡️ Supports broader role for RT in treatment planning 🔺 Maria Reig, MD, PhD Explore findings: https://ow.ly/gKa750Z9Rzc

🦠 Real-world evidence may help improve ADC safety Researchers found infection and hematologic AE risks varied substantially across antibody-drug conjugates, underscoring the importance of proactive monitoring. 🔸Jan et al | Cancers Learn more: https://ow.ly/oMJ450Z9Ryb

💊 A new all-oral regimen may ease treatment burden for older/frail patients with AML. In ASCERTAIN V, decitabine/cedazuridine + venetoclax induced CRs in 47%. ➡️ Study led to recent #FDA approval 🔹 Gail J. Roboz, MD | New England Journal of Medicine 🔗 https://ow.ly/YXoF50Z9RwT

🧬 In HPV-negative, PD-L1–positive, recurrent/metastatic HNSCC, ficerafusp alfa + pembrolizumab demonstrates: • 21% CR rate • Median OS: 21.3 months • Median response duration: 21.7 months 🔸 Glenn J. Hanna, MD of Dana-Farber 🔗 https://ow.ly/V2VI50Z2P9P

🖥️ #ACOAI: #AI-powered risk stratification continues to advance in prostate cancer care. Tempus and Artera are expanding access to a digital pathology–based prognostic test designed to estimate 5-year prostate cancer–specific mortality risk in mHSPC. 🔗 https://ow.ly/OC0650Z8WeO

🏥 About 1 in 3 eligible Americans remain unscreened for colorectal cancer New American Cancer Society guidelines add blood-based and expanded at-home testing options to help close that gap & improve early detection of a preventable disease. Learn more 👉 https://ow.ly/5klq50Z8Wcu

💉Updated KEYNOTE-942 results show durable benefits with intismeran autogene neoantigen therapy + pembrolizumab, including improved recurrence-free, distant metastasis–free survival in high-risk resected melanoma. 🗣️ Janice Mehnert, MD | ASCO 2026 https://ow.ly/ZNih50Z8Wav

💉 Data from Dr. Elizabeth McDonald at ASCO 2026 suggest GLP-1 exposure may be associated with lower breast cancer incidence. Retrospective analysis: GLP-1 treatment use was linked to reduced breast cancer detection among women undergoing imaging. https://ow.ly/7FG550Z8NIY

⚠️Risk prediction is central to breast cancer screening and prevention decisions A new Cochrane review suggests current risk models have limited accuracy in women with a family history, even as some perform better than others. 👩‍⚕️ Sarah McGarrigle, MD | ASCO 2026 https://ow.ly/vInU50Z8NFx

🚺 Updated NRG-GY018 data suggest pembrolizumab + chemotherapy continues to deliver durable survival benefits in advanced or recurrent #endometrialcancer, regardless of MMR status. • 48-month OS: 79% vs 60% 🔹 Ramez N. Eskander, MD | ASCO 2026 https://ow.ly/hBgP50Z8NEA

🫁 ASCO AI: Data presented at ASCO 2026 highlight how #AI-enabled workflows can improve lung cancer screening. Results included: ✅ Higher lung cancer screening uptake ✅ More stage I diagnoses ✅ Fewer late-stage presentations Explore the findings ➡️ https://ow.ly/EuzT50Z7ZJu

👤 Phase III data in advanced HNSCC: Triple oral metronomic chemo + ultra-low-dose nivolumab improved median OS from 6.2 to 10.3 months and reduced toxicity vs platinum chemo. ➡️ Potential for lower-cost treatment 🔹 Minit Jalan Shah, MBBS, MD | ASCO 2026 https://ow.ly/BVzl50Z7ZIG